Bank of Montreal Can Has $42.46 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

Bank of Montreal Can decreased its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 11.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 216,088 shares of the medical research company's stock after selling 27,103 shares during the quarter. Bank of Montreal Can owned 0.12% of IQVIA worth $42,463,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Pine Valley Investments Ltd Liability Co increased its position in shares of IQVIA by 0.5% during the third quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company's stock worth $2,247,000 after acquiring an additional 50 shares in the last quarter. Howard Capital Management Inc. grew its stake in IQVIA by 4.9% in the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company's stock valued at $225,000 after buying an additional 54 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in IQVIA by 1.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company's stock valued at $1,068,000 after acquiring an additional 56 shares during the period. Cypress Wealth Services LLC increased its stake in shares of IQVIA by 4.8% during the fourth quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company's stock worth $244,000 after purchasing an additional 57 shares during the period. Finally, Harbor Investment Advisory LLC grew its holdings in IQVIA by 4.7% in the 4th quarter. Harbor Investment Advisory LLC now owns 1,286 shares of the medical research company's stock valued at $253,000 after buying an additional 58 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on IQV shares. Robert W. Baird decreased their target price on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 21st. Citigroup dropped their price target on IQVIA from $225.00 to $210.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. BTIG Research downgraded shares of IQVIA from a "buy" rating to a "neutral" rating in a research note on Monday, February 3rd. Morgan Stanley boosted their target price on shares of IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a research report on Tuesday, February 11th. Finally, Barclays reissued an "equal weight" rating and issued a $170.00 price objective (down from $235.00) on shares of IQVIA in a research note on Thursday, April 10th. Six research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $241.50.

IQVIA Trading Up 0.9 %

IQVIA stock traded up $1.36 during mid-day trading on Wednesday, hitting $150.51. 330,231 shares of the stock were exchanged, compared to its average volume of 1,655,688. The stock has a market capitalization of $26.54 billion, a price-to-earnings ratio of 20.07, a PEG ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a 12 month low of $135.97 and a 12 month high of $252.88. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm's fifty day simple moving average is $180.02 and its two-hundred day simple moving average is $198.45.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.